The efficacy and safety of sublingual immunotherapy in children and adult patients with allergic rhinitis |
| |
| Affiliation: | 1. Department of Otorhinolaryngology & Head and Neck Surgery, Hainan General Hospital, Haikou 570311, China;2. Department of Otorhinolaryngology, The Affiliated Hospital of Qingdao University, Qingdao 266003, China;1. Research and Development, Merck & Co., Inc., Kenilworth, NJ;2. Division of Allergy & Immunology, University of South Florida Morsani College of Medicine, Tampa, Fla;3. ALK, Hørsholm, Denmark;4. Department of Medicine, National Jewish Health, Denver, Colo;1. Merck & Co, Inc, Kenilworth, New Jersey;2. Allergy Associates Medical Group, Inc, San Diego, California;3. Bernstein Clinical Research Center and Division of Immunology and Allergy, University of Cincinnati, Cincinnati, Ohio;4. Asthma & Allergy Associates, Chester, Pennsylvania;6. Minneapolis Allergy & Asthma Specialists, Minneapolis, Minnesota;1. Department of Pulmonology, Division of Allergy, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Paris, France;2. Allergy Outpatient Clinic, Rennweg, Vienna, Austria;3. ALK, Hørsholm, Denmark;4. Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen, Denmark;5. Allergy & Asthma Center Westend, Outpatient Clinic & Research Center, Berlin, Germany;1. Stallergenes S.A., Antony, France;2. UPRES EA 220, Clinical Research Unit, Foch Hospital, Suresnes, France;3. Allergy and Asthma Research Centre, Ottawa, Ontario, Canada;1. Division of Allergic Diseases, Mayo Clinic, Rochester, Minn;2. Center for Rhinology and Allergology, Wiesbaden, Germany;3. Department of Otorhinolaryngology, Head and Neck Surgery, Universitatsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany;1. Clinical Department of Internal Disease, Dermatology and Allergology in Zabrze, Medical University of Silesia in Katowice, Katowice, Poland;2. Medical Center LA Dymek, Strzelce Opolskie, Poland |
| |
| Abstract: | BackgroundClinical research has shown that sublingual immunotherapy (SLIT) is effective and safe in moderate-severe allergic rhinitis (AR) induced by house dust mite (HDM). However, the sample size in many studies is small. Meanwhile, the controversy on the efficacy and safety in the very young children younger than four years old still existed.ObjectiveThe aim of this retrospective study is to evaluate the efficacy and safety of SLIT with Dermatophagoides farinae (Der.f) extracts in children and adult patients with allergic rhinitis, particularly in the very young children.MethodA total of 573 subjects aged 3–69 with AR received a three-year course of sublingual immunotherapy with Der.f extracts along with pharmacotherapy. The total nasal symptoms score (TNSS), total medication score (TMS), visual analogue score (VAS) and adverse events (AEs) were evaluated at each visit.ResultTNSS, TMS, VAS were significantly improved during the three-year course of treatment in comparison to the baseline values (P < 0.01). Besides, significant improvement in nasal symptoms and reduction of medication use were also observed in young children aged 3–6 years (P < 0.01). No severe systemic adverse events (AEs) were reported.ConclusionSLIT with Der.f drops is clinically effective and safe in children and adult patients with HDM-induced AR, including the very young children less than four years old. |
| |
| Keywords: | Allergic rhinitis Sublingual immunotherapy Efficacy Young children |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
